Sometimes help may not be enough

AIDS

Volumn 17, Issue 8, 2003, Pages 1249-1251

  Lederman, Michael M ^a   Douek, Daniel C ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; FREUND ADJUVANT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VACCINE; PEPTIDE; PERFORIN; SUBUNIT VACCINE; T LYMPHOCYTE RECEPTOR;

ANTIBODY PRODUCTION; CHRONIC PATIENT; CROSS REACTION; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; EPSTEIN BARR VIRUS; HELPER CELL; HOST SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INFECTION CONTROL; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NOTE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL; VACCINATION; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS LOAD; VIRUS MORPHOGENESIS; VIRUS REPLICATION;

AIDS VACCINES; CD4 LYMPHOCYTE COUNT; CYTOTOXICITY, IMMUNOLOGIC; HIV INFECTIONS; HUMANS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0037529289     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305230-00018     Document Type: Note

References (26)

1. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 10(6)/L CD4 cell counts: a randomized controlled trial. JAMA 2000; 284:2193-2202.
2. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001; 75:11983-11991.
3. Gea-Banacloche JC, Migueles SA, Martino L, Shupert WL, McNeil AC, Sabbaghian MS, et al. Maintenance of large numbers of virus-specific CD8+ T cells in HIV- infected progressors and long-term nonprogressors. J Immunol 2000; 165: 1082-1092.
4. Dalod M, Dupuis M, Deschemin JC, Goujard C, Deveau C, Meyer L, et al. Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J Clin Invest 1999; 104:1431-1439.
5. Yu XG, Addo MM, Rosenberg ES, Rodriguez WR, Lee PK, Fitzpatrick CA, et al. Consistent patterns in the development and immunodominance of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses following acute HIV-1 infection. J Virol 2002; 76:8690-8701.
6. Lieberman J, Shankar P, Manjunath N, Andersson J. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 2001; 98:1667-1677.
7. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001; 410:106-111.
8. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al. HIV-specific CD8(+) T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068.
9. Matloubian M, Concepcion RJ, Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 1994; 68:8056-8063.
10. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression [see Comments]. Nat Med 1999; 5:518-525.
11. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000; 97:3382-3387.
12. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95-98.
13. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease [see Comments]. Science 1997; 277:112-116.
14. Lederman MM, Connick E, Landay A, Kuritzkes DR, Spritzler J, St Clair M, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178:70-79.
15. Rock KL, Gamble S, Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 1990; 249:918-921.
16. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000; 192:1685-1696.
17. Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 2002; 17:211-220.
18. Larsson M, Fonteneau JF, Bhardwaj N. Dendritic cells resurrect antigens from dead cells. Trends Immunol 2001; 22:141-148.
19. Horner AA, Datta SK, Takabayashi K, Belyakov IM, Hayashi T, Cinman N, et al. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J Immunol 2001; 167:1584-1591.
20. Steinman RM. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J Med 2001; 68:106-166.
21. Ghanekar SA, Nomura LE, Suni MA, Picker LJ, Maecker HT, Maino VC. Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin Diagn Lab Immunol 2001; 8:628-631.
22. Phillips RE, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354:453-459.
23. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995; 1:330-336.
24. Ciurea A, Hunziker L, Martinic MM, Oxenius A, Hengartner H, Zinkernagel RM. CD4+ T-cell-epitope escape mutant virus selected in vivo. Nat Med 2001; 7:795-800.
25. Valdez H, Mitsuysasu R, Landay A, Sevin A, Chart ES, Spritzler J, et al. Despite increasing CD4+ lymphocyte numbers, interleukin-2 does not enhance responses to immunization (results of ACTG 5046). J Infect Dis 2003; 187:320-325.
26. Gamadia LE, ten Berge IJ, Picker LJ, van Lier RA. Skewed maturation of virus-specific CTLs? Nat Immunol 2002; 3:203.